Androstane carbothioates
Patent 4335121 Issued on June 15, 1982. Estimated Expiration Date: 
February 13, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 13, 2001. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 3636010 3828080 Pharmaceutical compositions of 6,9-difluoro-androst-4-ene-17ଲ-carboxylates and derivatives thereof Thioetianic acid derivatives Patent #: 4188385 InventorsAssigneeApplicationNo. 06/234113 filed on 02/13/1981US Classes:514/180, 9-position substituted514/179, Modified C-ring (except methyl in 13-position) (e.g., double bond containing, substituted, etc.)514/181, 21-position substituted552/528, The carbon is double bonded directly at the 16-position552/610Acyclic carbon bonded directly at the 17 beta-position of the cyclopentanohydrophenanthrene ring system (e.g., etiocholanic acids, 17 cyanoetiocholanes, 17-aldehydrostanes, etc.)ExaminersPrimary: Roberts, Elbert L.Attorney, Agent or FirmInternational ClassesC07J 41/00 (20060101)C07J 31/00 (20060101) C07J 71/00 (20060101) C07J 3/00 (20060101) Foreign Application Priority Data1980-02-15 GBAbstractCompounds of the formula ##STR1## wherein R1 represents a fluoro-, chloro- or bromo-methyl group or a 2'-fluoroethyl group, R2 represents a group COR6 where R6 is a C1-3 alkyl group or OR2 and R3 together form a 16,17-isopropylidenedioxy group; R3 represents a hydrogen atom, a methyl group (which may be in either the - or ଲ-configuration) or a methylene group; R4 represents a hydrogen, chlorine or fluorine atom; R5 represents a hydrogen or fluorine atom and symbol represents a single or double bond have good anti-inflammatory activity, particularly on topical applications.The compounds of formula I are prepared by esterification, halogenation, reduction, deprotection and reaction at a 9,11-double bond to form a 9-halo-11ଲ-hydroxy grouping.Pharmaceutical compositions containing the compounds of formula I and methods for the use of the compounds are described and claimed. |
| ||||||||||||||
